Effect of triple growth factor controlled delivery by a brushite-PLGA system on a bone defect.
Bone regeneration is a complex process that involves multiple cell types, growth factors (GFs) and cytokines. A synergistic contribution of various GFs and a crosstalk between their signalling pathways was suggested as determinative for the overall osteogenic outcome. The purpose of this work was to develop a brushite-PLGA system, which controls the release rate of the integrated growth factors (GFs) to enhance bone formation. The brushite cement implants were prepared by mixing a phosphate solid phase with an acid liquid phase. PDGF (250 ng) and TGF-β1 (100 ng) were incorporated into the liquid phase. PLGA microsphere-encapsulated VEGF (350 ng) was pre-blended with the solid phase. VEGF, PDGF and TGF-β1 release kinetics and tissue distributions were determined using iodinated ((125)I) GFs. In vivo results showed that PDGF and TGF-β1 were delivered more rapidly from these systems implanted in an intramedullary defect in rabbit femurs than VEGF. The three GFs released from the brushite-PLGA system remained located around the implantation site (5 cm) with negligible systemic exposure. Bone peak concentrations of approximately 4 ng/g and 1.5 ng/g of PDGF and TGF-β1, respectively were achieved on day 3. Thereafter, PDGF and TGF-β1 concentrations stayed above 1 ng/g during the first week. The scaffolds also provided a VEGF peak concentration of nearly 6 ng/g on day 7 and a local concentration of approximately 1.5 ng/g during at least 4 weeks. Four weeks post implantation bone formation was considerably enhanced with the brushite-PLGA system loaded with each of the three GFs separately as well as with the combination of PDGF and VEGF. The addition of TGF-β1 did not further improve the outcome. In conclusion, the herein presented brushite-PLGA system effectively controlled the release kinetics and localisation of the three GFs within the defect site resulting in markedly enhanced bone regeneration.
Department of Chemical Engineering and Pharmaceutical Technology, University of La Laguna, 38200 La Laguna, Spain.
Ricardo
R
Reyes
Beatriz
B
De la Riva
Araceli
A
Delgado
Antonio
A
Hernández
Esther
E
Sánchez
Carmen
C
Évora
D000818:Animals; D001843:Bone Cements / Q000494:pharmacology; D001861:Bone Regeneration / Q000187:drug effects*; D002130:Calcium Phosphates / Q000494:pharmacology*; D003692:Delayed-Action Preparations / Q000493:pharmacokinetics; D005264:Femoral Fractures / Q000188:drug therapy*; D019344:Lactic Acid / Q000494:pharmacology*; D008297:Male; D008863:Microspheres; D010982:Platelet-Derived Growth Factor / Q000493:pharmacokinetics*; D011100:Polyglycolic Acid / Q000494:pharmacology*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011817:Rabbits; D054457:Tissue Scaffolds; D053773:Transforming Growth Factor beta1 / Q000493:pharmacokinetics*; D042461:Vascular Endothelial Growth Factor A / Q000493:pharmacokinetics*
D001843:Bone Cements; D002130:Calcium Phosphates; D003692:Delayed-Action Preparations; D010982:Platelet-Derived Growth Factor; D053773:Transforming Growth Factor beta1; D042461:Vascular Endothelial Growth Factor A; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; C494366:calcium phosphate, dibasic, dihydrate